ClinicalTrials.gg
Not yet recruitingNCT07298915EXER-MEDUpdated May 6, 2026

The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)

A Phase 3 interventional study of Tirzepatide and Exercise in Obesity & Overweight, sponsored by University of Virginia. Not yet recruiting at 1 site in United States. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Virginia · Phase 3, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies in Obesity by University of Virginia — 7 open to participants now, 10 under way, 1 of them phase 3. Obesity · University of Virginia.

Planned enrollment
10th of 20
24 · median 23
Started
2026
with 2 others
Phase 3
Only one
of the 23
Registered
22nd of 23
by date

Among the 23 studies in Obesity by University of Virginia, this one is the 10th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is the only one in phase 3, and was the 22nd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

7 of the 23 studies in Obesity by University of Virginia are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Obesity by University of Virginia, or all of them as a file.
02

Study summary

This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity.

The main questions it will answer includes:

  • Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone
  • Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life

Participants will:

  • Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician
  • (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training
  • Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures
Read the detailed description

The new type class of weight loss medications called GLP-1 medications have been shown to cause weight loss and improve risk factors for heart disease and diabetes. One thing that is currently unknown is whether exercise augments the impact of weight loss in people taking GLP-1 medication. The EXER-MED study is a pilot study evaluating the effect of 16 weeks of exercise training with GLP-1 medication compared to taking the medication alone. We will evaluate the impact of the study groups on weight, body composition (percent fat, percent lean mass), blood pressure, arterial stiffness, blood work (cholesterol, blood pressure, glucose, insulin) and quality of life.

03

Conditions studied

  • Obesity & Overweight

Keywords

  • Obesity
  • Overweight
  • Exercise
  • aerobic
  • resistance training
  • GLP-1
  • Weight loss
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women 30-65 years of age, women included
  • 27-29.9 with an additional CVD risk factor or 30-40 kg/m2
  • For overweight adults only: additional cardiometabolic risk factor (diagnosed dyslipidemia, hypertension)
  • Willingness and adequate health to go on weight loss medication
  • The capability and willingness to provide written
  • Approval of their primary care provider to go on weight loss medication

Exclusion criteria

Exclusion Criteria:

  • Including but not limited to serious arrhythmias
  • Cardiomyopathy
  • Congestive heart failure
  • Stroke or
  • Peripheral vascular disease
  • Previous history of myocardial infarction or stroke
  • Previous diagnosis or taking medication for type 1 or 2 diabetes, fasting glucose >125 mg/dL or ≥6.5%
  • Systolic blood pressure >160 mmHg and diastolic blood pressure >100 mmHg.
  • Hospitalization for mental illness within the past 5 years or currently undergoing treatment for severe mental illness
  • Conditions that can be aggravated or are by exercise training
  • Plans to be out of town more than 3 weeks in the next 4 months.
  • Currently pregnant or plans to become pregnant
  • Currently in a diet or exercise program
  • Non-compliance during screening or extreme difficulty in obtaining baseline blood samples
  • Enrolled in a different exercise program
  • Previous weight loss surgery
  • Use of weight loss medication within the last year
  • hypo/hyper thyroid (medicated or unmedicated)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Exercise

    Participants will perform aerobic and resistance exercise while taking monthly tirzepatide for 16 weeks

    Drug: Tirzepatide · Behavioral: Exercise

  • Active comparator
    Standard Care

    Participants will take monthly Tirzepatide under the care of their primary care provider for 16 weeks

    Drug: Tirzepatide

Interventions

  • Participants will take tirzepatide under the care of their primary care provider for 16 weeks

  • BehavioralExercise

    Participants will perform a combination of aerobic and resistance training for 16 weeks

06

What researchers measure

Primary outcomes

  1. Weight

    Measurement will be taken 3 times and measured in kg. A positive value indicates an increase in weight and a negative value indicates a reduction in weight

    Time frame: Baseline and 16 Weeks

Secondary outcomes

  1. Physical activity level

    Physical activity will measured via accelerometry (total steps and light, moderate, vigorous physical activity) and steps for 7 consecutive days

    Time frame: Baseline and 16 weeks

  2. Changes in Blood Lipids Concentrations

    A fasting blood sample will be used to measure low density lipoprotein, high density lipoprotein, total cholesterol, and triglycerides will be measured. It will be quantified as the specific amount of the lipoprotein within the blood in mg/dL for all lipid variables. Participants will be fasted at least 12 hours prior to the blood draw. Change will be quantified as the week 16 value subtracted from the baseline value. A positive value indicates an increase in the blood lipid variable and a negative value is associated with a reduction in the variable.

    Time frame: Baseline to 16 weeks

  3. Resting Metabolic Rate

    Resting metabolic rate (RMR) will be measured in a quiet, temperature-controlled room using indirect calorimetry with a clear ventilated canopy and dilution pump. An increase represents a positive change and a decrease represents a negative change

    Time frame: Baseline and 16 Weeks

  4. Change in Fasting Glucose Level

    Change in fasting glucose level. Fasting glucose level refers to the concentration of glucose within the blood (mg/dL). The change in fasting glucose level is quantified by subtracting the week 16 value from the baseline value. Thus, a positive value indicates an increase in glucose level and a negative value indicates a decrease in glucose.

    Time frame: Baseline to 16 Weeks

  5. Change in Fasting Insulin Level

    Fasting insulin represents the concentration of insulin in the blood. A positive value represents an increase in insulin concentration and a negative value represents a decrease in insulin concentration.

    Time frame: Baseline to 16 Weeks

  6. Change in Augmentation Index

    Central Arterial stiffness will be measured using a SphygmoCor XCEL (Itasca, IL). Participants will refrain from large meals and caffeine for at least 2 hours and alcohol, vigorous exercise and vasoactive medication for at least 12 hours. Testing will occur in a quiet temperature controlled room in the seated position after a 5 minute rest. Augmentation index represent central arterial stiffness and will be quantified via augmentation index (%). The augmentation index (AIx) is a measure of systemic arterial stiffness, and is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A lower value indicates better stiffness

    Time frame: Baseline to 16 Weeks

  7. Changes in Blood Pressure (mmHg)

    Brachial and aortic blood pressure will be measured using a sphygmocor XCEL. Blood pressure is quantified in mmHg and will be taken in the seated position after a 5 minute rest. Change in blood pressure is quantified by subtracting the week 10 value from the baseline value. Thus, a positive number is associated with an increase in blood pressure across the time point and a decrease indicates a decrease in blood pressure

    Time frame: Baseline to 16 weeks

  8. Change in hemoglobin A1C

    Hemoglobin A1C (%) will be measured at baseline and 16 weeks. Change in hemoglobin A1C will be determined by subtracting the week 16 value from baseline. A positive change indicates and increase in hemoglobin A1C and a negative value indicates a decrease in hemoglobin A1C.

    Time frame: Baseline and Week 16

  9. Change in Waist Circumference

    Waist circumference will be measured at the natural waist (midway between the inferior border of the rib cage and the superior aspect of the iliac crest) with a gulick tape measure. Both landmarks (the inferior border of the ribcage and the superior aspect of the iliac crest) will be marked and the distance will be measured to determine the appropriate measurement site. Staff will confirm that: 1) the measurement tape remains horizontal; 2) the tape touches the entire circumference of the participant; 3) abdominal tissue is not compressed; 3) the tape measure is not within abdominal folds; 4) the measurement is taken at the end of normal respiration. The measurement will be repeated an additional time, and the reported value will be the average of these measurements. Both measurements must be within 0.5 cm to be considered acceptable for data purposes. The change in waist circumference will be quantified as the the week 16 value subtracted from the baseline value

    Time frame: Baseline to Week 16

  10. Change in Body Composition (Fat mass or Lean Mass)

    Dual-energy X-ray absorptiometry will be used to measure changes in fat mass and lean mass. Body fat will be quantified as the percent of fat relative to the total body composition. Lean mass will be quantified as the percent of lean tissue relative to the total body composition. Change in these variables will be quantified as by subtracting the week 16 value from the baseline value. Thus, a change in positive direction is associated with an increase in body fat or lean mass and a negative value represent a decrease.

    Time frame: Baseline to Week 16

  11. Change in Cardiorespiratory Fitness

    Fitness will be measured using a modified Balke protocol on a treadmill. Participants will walk at an initial speed of 2.0 mph with 0% grade for the first 3 minutes after which the treadmill speed will increase to 3.0 mph for the next 3 minutes. The treadmill grade will be increased by 2.5% every 3 minutes until volitional exhaustion. Fitness will be quantified in absolute terms (VO2) L/min, relative (VO2 mL/kg/min) and Estimated METs. Change in fitness will be quantified by subtracting the week 16 value from the baseline value. A positive value will indicate and increase in fitness. A negative value will indicate a reduction in fitness.

    Time frame: Baseline and 16 Weeks

  12. Change in dietary quality

    Dietary quality is measured with the ASA 24-hour dietary recall (ASA 24) . The ASA 24 is web-based tool that allows individuals to self-report all foods and beverages consumed in the previous 24 hours (i.e., the data collection method). This allows us to track diet quality changes over time. Change in dietary outcomes will be quantified by subtracting week 16 values from baseline. A positive value will represent an increase in a variable. A negative value will represent a reduction in a variable.

    Time frame: Baseline to Week 16

  13. Quality of Life (IWQL-Lite)

    Measured by the questionnaire Impact of Weight on Quality of Life-Lite (IWQL-Lite) at baseline and Week 16. Scores range from 0 to 100, with 100 representing the best quality of life. Change in quality of life will be expressed by subtracting Week 16 from baseline level. An increase in quality of life will be represented by a positive value. A negative value represents a reduction in quality of life.

    Time frame: Baseline to Week 16

  14. Change in isokinetic dynamometry

    Isokinetic knee flexor and extensor muscles strength and endurance will be evaluated with the isokinetic dynamometer. Change in strength and endurance outcomes will be quantified by subtracting the the Week 16 value from the baseline value. A positive value will indicate an increase in strength or endurance. A negative value will indicate a reduction in strength or endurance.

    Time frame: Baseline and Week 16

07

Study locations

1 site
  • University of Virginia
    Charlottesville, Virginia 22901, United States
    • Damon L Swift, Ph.D. · Contact(434) 924-1436
    • Damon L Swift, Ph.D. · Principal investigator
    • Catherine Varney, DO · Sub investigator
    • Jay Hertel, Ph.D. · Sub investigator
    • Sibylle Kranz, Ph.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2026, 4 months later.

Of 63 non-industry phase 3 interventional studies under Obesity, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 56. This study's planned 4 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Dec 23, 2025
StartEst.
Aug 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07298915
Responsible party
Damon Swift (Associate Professor, University of Virginia) — Principal investigator
First posted
Dec 23, 2025
Start date
Aug 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 6, 2026

Study contacts

Damon L Swift, Ph.D.
Contact
dls3s@virginia.edu
(434) 924-1436
Damon L Swift, Ph.D
principal investigator · University of Virginia

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion